News Hub | News Direct

MedCognetics Introduces the First Embedded AI Cancer Detection System for Mammography Imaging

MedCognetics

MedCognetics, Inc., a company focusing on medical imaging AI, today announced the successful testing and implementation of the first embedded AI image processing and cancer detection system for mammography. The system utilizes the NVIDIA IGX Orin TM medical-grade edge AI platform alongside MedCognetics’ advanced AI-enabled software, CogNet AI-MT, which was developed in collaboration with clinical leaders worldwide. CogNet AI-MT has been trained on a diverse global dataset to enhance the performance of radiologists and help improve patient outcomes worldwide. Incorporating MedCognetics’ new system would allow for AI-driven image enhancement and cancer detection to occur in real-time within the mammography device itself. The embedded solution eliminates latency, delivering immediate, high-quality image analysis, a significant improvement over traditional setups that require external workstations or cloud-based processing. This approach is poised to improve patient outcomes through faster results, enhanced image quality and reduced hardware costs. “Embedding our CogNet AI-MT software directly into mammography imaging equipment means we can enhance image quality and provide immediate cancer detection without the need for costly hardware upgrades,” said Debasish “Ron” Nag, CEO of MedCognetics. “Using the NVIDIA IGX platform, we’re advancing medical imaging technology, making high-quality diagnostic tools more accessible to radiologists and imaging centers around the world.” The NVIDIA IGX Orin platform combines enterprise-level hardware, software, and support. It is purpose-built for industrial and medical edge computing. The platform delivers the performance, durability, security, and safety required for advanced AI applications and features programmable safety extensions, commercial OS support, and powerful AI software. These capabilities, equip organizations to confidently deploy AI safely and securely for enhanced human and machine collaboration. The embedded AI system developed by MedCognetics offers several key benefits: On-Premises Device: Rapid, complete analysis right in the radiology workflow. Enhanced Image Quality: AI-driven enhancements improve the clarity and detail of images without requiring high-end, expensive hardware. Immediate Results: Processing occurs within the device, providing instant analysis and reducing the wait time for results. Cost Efficiency: Medical device manufacturers can achieve high-end image quality at a fraction of the cost by utilizing AI rather than upgrading hardware. Workflow Optimization: Enables worklist prioritization and clinic-determined workflow optimization, enhancing the accuracy and efficiency of radiologists and imaging centers. Easy Upgrades and Maintenance: Software-based solutions are easier to update and maintain, helping to ensure that medical imaging equipment remains cutting-edge without frequent hardware replacements. Earlier this year, MedCognetics was awarded a groundbreaking patent by the United States Patent and Trademark Office (USPTO) for its inclusive, unbiased medical imaging AI technology in mammography. Its expertise in embedded engineering, combined with the NVIDIA IGX platform, is poised to significantly advance medical imaging technology. This work underscores the importance of integrating AI into medical devices to enhance diagnostic capabilities and patient care. For more information about this new embedded AI cancer detection system, visit here. About CogNet AI-MT® CogNet AI-MT is part of MedCognetics' comprehensive CogNet AI™ platform, designed to enhance radiologists' capabilities by expanding insights and awareness in medical imaging. This unbiased platform, trained on a diverse global dataset, advances the performance of radiologists and imaging centers, delivering accurate care for patients worldwide. CogNet AI-MT employs advanced AI and Machine Learning (ML) to detect early signs of cancer across all ethnicities and can be deployed on customer premises, in the cloud, or via the web. The platform is FDA 510(k) cleared for triage of mammogram images. Useful Links: Learn More: www.medcognetics.com Follow us: X | LinkedIn Sales and Partnership Inquiries: Please contact MedCognetics, Inc. at: media@medcognetics.com About MedCognetics, Inc. MedCognetics provides an advanced AI software platform that integrates into radiology workflow. In addition, the AI algorithm is trained on a diverse global patient dataset to mitigate data biasing. The future of AI in healthcare is unbiased services and MedCognetics is at the forefront of creating a more predictable medical outcome and ultimately saving lives. Founded in 2020, the company is based in Dallas, Texas. For more information, please visit our website at www.medcognetics.com. # # # Contact Details ANW Networks Alicia Nieva-Woodgate +1 415-515-0866 alicia@anwnetworks.com Company Website https://www.medcognetics.com

October 10, 2024 11:15 AM Eastern Daylight Time

SBC Medical Group (Nasdaq: SBC) Earnings Update: H1 2024 Revenue Up 29% And Net Income Up 123%

Benzinga

By Gerelyn Terzo, Benzinga After successfully completing its business combination with Pono Capital in September, SBC Medical Group (NASDAQ: SBC) has been trading on the Nasdaq under the symbol “SBC”, marking a key moment in its transition as a global company The listing on the Nasdaq is expected to provide SBC Medical with access to capital while bolstering its partnership opportunities and paving the way for an expansion in the U.S. and South Asian markets. Tokyo-based SBC Medical has already gained a reputation as a go-to medical services company specializing in the aesthetic medical industry. After paving the way in Japan, where it reports it has built the biggest network of franchised clinics in the country, SBC Medical has now set its sights on an international expansion, including the broader South Asian and U.S. markets, where it intends to maintain the high standards which drove its growth in Japan. Led by renowned industry executive Dr. Yoshiyuki Aikawa, SBC Medical seems to have the wind at its back, as evidenced by a strengthening balance sheet in H1 2024. Despite economic headwinds, the company continued to grow its available cash in the period in excess of $115 million on a pro forma combined basis while also managing to increase net income more than twofold year-over-year and growing revenue while honing expenses. SBC Medical’s Financial Performance In H1 2024, SBC Medical reported revenue of $107.9 million, an increase of 28.6% compared to $83.9 million in the first half of 2023. SBC Medical more than doubled its net income to $37.2 million from $16.6 million in H1 2023. Growth Opportunities In Japan Given SBC Medical’s performance so far in 2024, the company has set its sights on further growth opportunities, particularly in Japan, where it says it already enjoys a competitive advantage. SBC recognizes an opportunity for further growth there as it continues to solve some critical pain points for doctors, allowing physicians to focus on their patients. SBC Medical’s fully digitized integrated system streamlines processes like customer flow and human resources, while its educational system offers a quality patient experience at its franchisees. Additionally, SBC’s extensive network of franchise clinics empowers doctors to hone their skill sets in diverse medical treatments. As for its expansion, SBC Medical is targeting adjacent areas such as fertility treatments, hair loss solutions and online clinic services, all of which present robust growth and profit potential. The company believes its reputation should pave the way for strategic business-to-business partnerships to accelerate growth. SBC Medical seems well-positioned to capitalize on these opportunities with its strong balance sheet. With its recent listing, SBC Medical’s growth story is just getting underway. Investors who are interested in taking a front seat to the action can learn more about the company here. Featured photos courtesy of SBC Medical Group. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 10, 2024 08:30 AM Eastern Daylight Time

Image

AGC Biologics Begins Operations at New State-of-the-Art Manufacturing Building in Copenhagen after Successful Inspection and Licensing from Danish Medicines Agency

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today the successful completion of the final milestone at its new manufacturing building at its Copenhagen site. The site received authorization and a license to begin production from the Danish Medicines Agency for its new four-story 19,000 m² manufacturing building in September, allowing it to begin official operations. AGC Biologics started production on its first project at the new building shortly after approval, a phase II/III clinical project. The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors, two complementary downstream suites, and dedicated warehouse and quality control laboratory spaces. The new building has doubled the capacity for mammalian manufacturing at the AGC Biologics Copenhagen manufacturing plant. “Getting operational approval from the Danish Medicines Agency was the final step in a three-year journey that many individuals have contributed to, and this milestone is one we were proud to celebrate as a site” said Andrea Porchia, General Manager of the Copenhagen site. “We now begin the work of producing more treatments at this facility than ever before and believe this is one of the best locations for developer partners seeking CDMO services in Europe.” AGC Biologics Copenhagen has an extensive operational track record and expertise spanning early-stage development through clinical and commercial manufacturing. It operates and supports drug substance projects using both mammalian and microbial systems and has produced seven commercial products. To learn more about AGC Biologics’ protein biologics manufacturing site in Copenhagen, visit https://www.agcbio.com/facilities/copenhagen. For more information on the company’s end-to-end global CDMO services in the U.S., Europe, and Japan, visit www.agcbio.com. About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. We currently employ more than 2,500 Team Members worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is a part of AGC Inc.’s Life Science Company. The Life Science company runs more than 10 global facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. Contact Details Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com Company Website https://www.agcbio.com/

October 10, 2024 12:07 AM Mountain Daylight Time

Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit

Silexion Therapeutics Corp

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced its participation in the 2024 Maxim Healthcare Virtual Summit, scheduled to take place from October 15 to 17, 2024. Ilan Hadar, Chief Executive Officer and Dr. Mitchell Shirvan, Chief Scientific and Development Officer will join a fireside chat hosted by Jason McCarthy, Senior Managing Director and Head of Biotechnology Research at Maxim Group, on Thursday, October 17, 2024, at 9:30am ET. The event will be streamed live on M-Vest and accessible to members by clicking here or via following link: https://m-vest.com/events/healthcare-10152024. The Company’s management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact their Maxim representative to schedule a meeting. About Silexion Therapeutics: Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com Contact Details Silexion Therapeutics Corp Ms. Mirit Horenshtein Hadar, CFO mirit@silexion.com ARX | Capital Markets Advisors North American Equities Desk silexion@arxadvisory.com

October 09, 2024 04:30 PM Eastern Daylight Time

NAVEX Unveils Curated AI Content Library to Simplify Compliance and Risk Mitigation

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management software, introduces its new AI-focused content library designed to help organizations address the rapidly evolving landscape of Artificial Intelligence (AI) regulations and frameworks. As AI technologies become part of daily operations, many organizations find themselves entering uncharted waters regarding effective AI governance. According to Forrester’s September 2023 Artificial Intelligence Pulse Survey, 56% of AI decision-makers said their organization will use generative AI (genAI) in the next 12 months for internal or customer-facing production applications for employee productivity. The stakes are rising, and navigating these challenges without a clear framework can feel overwhelming, leaving companies vulnerable to risks. NAVEX plays a critical role by enabling companies to implement strong controls, automate workflows, and perform comprehensive testing. This approach simplifies complex challenges and transforms them into strategic opportunities. NAVEX’s content library is continuously curated to cover international and industry-specific AI regulations, including emerging standards and compliance requirements. By leveraging this resource, customers can ensure their AI initiatives align with ethical guidelines and regulatory mandates. A.G. Lambert, Chief Product Officer at NAVEX, captures the pivotal moment many organizations face: "As AI technologies revolutionize industries, companies find themselves standing at a crossroads, navigating the intricate landscape of effective AI governance. Our AI content not only empowers risk management professionals to establish crucial controls but also enhances efficiency by automating compliance processes. This dual approach enables organizations to embrace AI technology with confidence, transforming challenges into opportunities for growth and innovation." Key features of the NAVEX AI content library include: Centralized AI Regulatory Resources: Access a consolidated library of global AI regulations and industry-specific guidelines. Streamlined Control Development: Simplify the process of creating and implementing AI-specific controls to align with emerging regulations. Automated Compliance Monitoring: Leverage automation to track compliance requirements and ensure adherence through continuous control testing. Enhanced Risk Mitigation: Identify and mitigate AI-related risks proactively using structured regulatory frameworks. Future-Proof Compliance Strategy: Stay ahead of evolving AI laws and standards, ensuring the organization remains compliant and competitive. NAVEX is enhancing AI governance with its NAVEX One platform that streamlines the process of developing and distributing AI-related policies, ensuring companies stay aligned with fast-changing compliance requirements in the AI landscape. Should employees or third parties have AI-related issues or concerns, the NAVEX One platform offers employees a secure solution to report them. This proactive approach helps organizations identify and mitigate potential risks early on. The NAVEX content library offers over 400 regulations and compliance frameworks, continuously expanding to meet the demands of an evolving regulatory environment. This extensive resource includes critical AI regulations such as the EU AI Act, NIST AI Risk Management Framework, and the Colorado Artificial Intelligence Act. As AI governance becomes increasingly critical, NAVEX integrates AI training, incident management, and policy management into this comprehensive resource, ensuring organizations stay ahead of compliance requirements. With real-time updates, businesses can select tailored content to meet emerging AI regulatory standards, providing the tools to navigate current and future compliance challenges effectively. This seamless integration helps organizations maintain a proactive risk and compliance posture while leveraging cutting-edge technologies. The new AI content library is now available as part of NAVEX’s Integrated Risk Management solution. For more information, visit NAVEX’s Website. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

October 08, 2024 08:00 AM Eastern Daylight Time

Former Senior Advisor To Obama Joins Forces With Innovative Biotech To Catch Cancer Early

Benzinga

By Johnny Rice, Benzinga Petra Smeltzer Starke, Brand Ambassador for Mainz Biomed (NASDAQ: MYNZ), was recently interviewed by Benzinga. Mainz creates clinical laboratory tests that save costs and lives by enabling early detection and prevention of disease. The company reports that patients with cancers and other conditions are living longer and enjoying better health because of medical innovations like the tests Mainz creates. Petra Smeltzer Starke is the new face of Mainz. As a former senior advisor to President Obama and a rectal cancer survivor, Mainz believes she is uniquely suited to help spread the word about early detection and help save lives. Watch the full interview here: Featured photo by Louis Reed on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 07, 2024 08:20 AM Eastern Daylight Time

Video Image

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Benzinga

By Josh Enomoto, Benzinga Introduced in the late 1990s, continuous glucose monitoring (CGM) revolutionized diabetes care. Prior to CGM, home blood glucose monitoring (BGM) methodologies – which involve patients using a lancet to prick their fingers and apply a drop of blood to a test strip – represented the norm. Still, even with the rise of CGM, several challenges remain. That’s what Glucotrack Inc. (NASDAQ: GCTK) is looking to address. In particular, while current CGM solutions have improved quality of life via informed decision-making, several obstacles – including discomfort and inconvenience – have left many patients as well as medical professionals wanting. Glucotrack aims to fill the opportunity gaps in the CGM industry by directly addressing the pain points of the contemporary standard of care. Most importantly, Glucotrack’s mainline innovation – known as the Continuous Blood Glucose Monitor (CBGM) – focuses on the patient. Diabetes affects 38 million people in the U.S. alone, according to the CDC, and it's the eighth leading cause of death, contributing to serious complications like kidney disease, blindness and cardiovascular risk. With such a vast population facing the daily burden of managing their blood sugar, innovations like Glucotrack’s real-time monitoring system could be essential to improving quality of life and healthcare outcomes. Assessing The Current State Of CGM Technology According to a publication posted by the National Library of Medicine, the U.S. Food and Drug Administration (FDA) approved the first “professional” CGM in 1999. Since that time, there have been several major advancements in the technology. However, commercially available CGMs tend to measure glucose in interstitial fluid and not directly from blood. And, until relatively recently, all CGM devices required calibration via blood glucose measurements extracted from the fingerstick process. Generally, the calibration process is used to improve system accuracy by comparing it to a blood glucose measurement from a fingerstick. Even with the latest advancements, several challenges and inconveniences remain. Among the most vexing for patients is a lack of a platform that addresses all major concerns. Instead, sufferers of diabetes must compromise across a range of different sets of pros and cons. Abbott Laboratories (NYSE: ABT) has established a strong presence in diabetes management with its CGM system, FreeStyle Libre. Libre offers accurate and continuous glucose monitoring, but the platform also requires frequent sensor changes (every 14-15 days, depending on the model) and the use of a wearable. Dexcom (NASDAQ: DXCM) is also among the leaders in CGM technology, offering accurate and continuous glucose tracking. However, reports indicate the company’s platform falls short in terms of the adhesive patch potentially not properly sticking to the patient’s skin at all times. Senseonics Holdings Inc. (AMEX: SENS) has gained in popularity thanks to its product Eversense, an implantable CGM with a sensor life of up to six months, with the FDA recently clearing use for one year. While an enticing proposition, the system requires frequent calibration and patients still need to wear a transmitter over the skin. Medtronic PLC (NYSE: MDT) represents another of the innovative powerhouses in diabetes care, with its CGM integrated into a broader diabetes management ecosystem. Nevertheless, the underlying platform still requires regular calibration and the use of wearables. In contrast, Glucotrack seeks to address these shortcomings of contemporary CGM devices. One of the most distinct advantages of the company’s solution is a much longer sensor life. Moreover, it does away with wearables while providing real-time blood glucose monitoring. Key Advantages Of The Glucotrack System As mentioned earlier, sensor life represents a core struggle of many diabetes patients managing their condition. On one end of the scale, Abbott’s FreeStyle Libre, Dexcom systems and Medtronic systems offer a relatively pain-free sensor application process. However, the sensor requires replacement after 7-15 days, depending on the model. On the other hand, Senseonic offers a sensor life of up to half a year, with one-year recently approved by the FDA. This system is implantable, but still requires the need for a wearable transmitter, which impacts the patient’s quality of life. Furthermore, according to internal market research performed by Glucotrack, 73% of endocrinologists favor devices with a sensor life of three years. As shared in an earlier Benzinga article, the key advantage of the Glucotrack system is that the underlying implantable CBGM features a sensor that can last up to three years. That’s a significant improvement over many more popular options, thus reducing the frequency and hassle of updating prescriptions and ordering supplies. Speaking of organic benefits, Glucotrack’s device eliminates the need for wearables. This advantage automatically resolves common concerns tied to continuous glucose monitoring, including adhesive skin irritation, sensor detachment during activities and the burden of managing supplies and copayments. Another important attribute of the Glucotrack system is its real-time blood glucose measurement capabilities. Such measurements may provide much more accurate readings because the use of blood dramatically cuts the lag time present in traditional interstitial glucose monitors. Significantly, real-time measurements may potentially facilitate improved safety. Thanks to the quicker testing data, patients may be able to respond more quickly to urgent matters, such as low or high blood sugar events. This attribute may potentially reduce the risk of severe complications like diabetic ketoacidosis or hypoglycemic coma. A core advantage that Glucotrack claims is CBGM’s broad interest among healthcare professionals. The company recently conducted proof of concept research among 100 endocrinologists and 50 primary care providers (PCPs), which yielded much data, including the following statistics: Finding the implantable CBGM concept an intriguing and innovative one, 42% of endocrinologists expressed willingness to adopt the platform following approval and at a sensor life of only two years. Even more so than endocrinologists, PCPs have vocally expressed eagerness to try the implantable CBGM, with 68% willing to adopt the system at a sensor life of only two years. Individual PCPs reported that Glucotrack’s device can be a “game changer for diabetics,” along with labeling the concept itself as “genius.” Finally, Glucotrack offers an intuitive interface, requiring minimal calibration and thus reducing the daily burdens that patients must follow. Rising Need For CGM Innovation According to Lancet’s global burden studies, chronic conditions represented the root of 74% of all deaths across the world. That’s a noticeable rise from 67% of deaths in 2010, reflecting the rising prevalence of chronic diseases, of which diabetes is one. As such, the rise of diabetes – particularly type 2 and prediabetes – represents a significant area of concern. However, for Glucotrack, the main focus is on insulin-using people with diabetes, as these patients require continuous monitoring due to insulin therapy. With this population segment also growing, finding advanced solutions to address their unique challenges becomes even more critical. It’s not just about the inconveniences of frequent sensor changes and the irritation and discomfort involved in everyday utilization of standard CGM devices. It’s often also limiting the ability to participate in some activities such as swimming or hot yoga due to concerns about the wearable falling off. By facilitating a long-lasting alternative, Glucotrack’s CBGM makes glucose monitoring less intrusive and potentially more accessible. Most significantly, the accuracy behind real-time glucose measurements reported by the company may potentially improve quality of life and in some acute situations save it. Empowering Diabetes Care With Real-Time Solutions In an ever-growing diabetes landscape, Glucotrack’s advancements in continuous glucose monitoring offer a potential solution to the persistent challenges faced by insulin-using people with diabetes. By addressing key pain points such as short sensor life, the discomfort of wearables and the hassle of frequent replacements, Glucotrack potentially positions itself as a transformative force in diabetes care. Additionally, with its reported real-time, accurate blood glucose measurements, long-lasting sensor and lack of an intrusive wearable, the CBGM system not only improves day-to-day management but also has the potential to prevent life-threatening complications. As the need for better diabetes care intensifies, Glucotrack is looking to offer a brighter, healthier future for millions of people managing this chronic disease. Featured photo by Brooke Cagle on Unsplash Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 04, 2024 08:30 AM Eastern Daylight Time

Image

Holiday Gift Guide: Add These Luxury Cannabis Items to Your Shopping List

MJ Attaché

Cannabis is legal in 38 states and counting for medical use. Almost 40% of women over the age of 21 currently consume cannabis, and men are nearly twice as likely to use cannabis than women. Odds are, your holiday gift-giving list includes an herbalist who would cherish an easy and elegant addition to their self-care ritual. “Whether the cannabis connoisseur on your holiday giving list uses cannabis medicinally or recreationally, MJ Attaché gift options elevate the experience and simplify the lives of discerning herbal enthusiasts,” explains MJ Attaché founder Christy Fuicelli. “Not only are our attachés statement pieces for self-care rituals, but they’re discreet, lockable and customizable to suit individual consumption needs.” New-to-market, MJ Attaché luxury holiday gift options for cannabis enthusiasts The Anthony Bag - $2,150.00 The Anthony bag combines style and sophistication for the discerning herbalist. Built by Italian artisans with the finest materials, this attaché dispels outdated stereotypes and elevates self-care rituals with patent-pending technology. It is the first on the market to provide a subtle, smell-disguising, practical and elegant solution to suit a cannabis enthusiast’s lifestyle. Available in five colors, The Anthony contains a removable rolling tray and magnetic accessories for customizable storage of your cannabis and accouterments. Retractable Vape Pen Holder - $150.00 Give the gift of ease, and the herbalist on your list will never lose another vape pen. Made in Italy of metal, leather and elastic, this accessory ensures the safekeeping and easy access of a favorite pen. The branded snap hook clips to bags or clothing, and the monogrammed retractable piece allows for use without removal. Fits most batteries up to.5″ in diameter. Retractable Lighter Holder - $175.00 Place this holder under the tree, and your favorite cannabis enthusiast’s lighter will always be at hand. Like the pen holder, this lighter holder is made in Italy of metal and leather. It is engineered to ensure a lighter’s safekeeping and easy access. The accessory’s branded snap hook clips to clothing or bags for accessibility, and the monogrammed retractable piece allows for use without removal. Fits classic BIC lighter. “Our vape pen and lighter holders keep your cannabis accessories safe and right where you need them. The Anthony is a luxury storage solution for all your cannabis needs—making it the perfect gift for a sophisticated herbal enthusiast,” says Fuicelli. “In addition to beauty and refinement, The Anthony is equally functional in that the components can be customized to meet individual needs. For example, edibles, flower and prerolls can be stored in the provided smell-proof jars and locked in The Anthony bag for safekeeping and transport this holiday season,” Fuicelli explains. The Anthony bag makes cannabis self-care rituals easy and elegant Discreet, smell-disguising design you can take anywhere Patent-pending modular elements include smell-proof jars for edibles and flower, lighter holder and glass holder Removable rolling tray for ease of use and clean-up Zipper lock eliminates need for difficult-to-open childproof containers "The Anthony bag not only keeps all my sesh products nicely organized for on-the-go, but it also turns heads. All my colleagues are shocked to find out its purpose!" says Arend Richard, The Anthony bag purchaser and founder of Cirrus Social Club in Denver. Find holiday luxury at MJAttache.com. Connect on Facebook and Instagram for the latest updates and deals. # # # About MJ Attaché Launched in April 2024, MJ Attaché is a designer and developer of high-quality, handmade Italian leather bags and accessories for the cannabis connoisseur. The luxury brand, with its moniker “MJ” (short for Mary Jane—an alias for marijuana), was founded by entrepreneur Christy Fuicelli, a stylish herbalist. Realizing a void in the marketplace, Fuicelli created MJ Attaché to cache and carry her cannabis in a discreet manner reflective of the luxury she enjoyed in other personal products. Fuicelli spent years designing beautifully crafted bags that embody elevated style, sophistication, high quality and fine craftsmanship. Appealing to men and women alike, MJ Attaché products bring ease and style to the cannabis industry and challenge outdated stigmas. Contact Details MJ Attaché Katie Converse for MJ Attaché info@mjattache.com Company Website https://mjattache.com/

October 03, 2024 01:00 PM Mountain Daylight Time

Image

PathAI Announces Collaboration with the Crohn’s & Colitis Foundation to Advance Novel IBD Research and Development

PathAI

PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced a partnership with the Crohn’s & Colitis Foundation. The collaboration will empower academic and biopharmaceutical researchers to unlock insights into inflammatory bowel disease (IBD) through the unique combination of quantitative histopathology data and well-characterized multi-modal clinical and molecular data. Quantitative histopathology data will be derived from the deployment of PathAI's IBD Explore ™ and AIM-HI UC ™ algorithm products 1 on digitized histology images from the Crohn’s and Colitis Foundation’s IBD Plexus Ⓡ dataset. The parties will also pursue collaborative research using their complementary assets aimed at advancing the field of IBD research. Despite the current array of treatment options in ulcerative colitis and Crohn’s disease, remission rates in induction trials are still less than 50%, revealing a therapeutic ceiling in the treatment of both diseases and potential challenges that need to be addressed 2-5. PathAI’s IBD Explore algorithm utilizes AI-powered histopathology analysis to provide detailed insights into the tissue’s inflammatory microenvironment. IBD Explore has the potential to lead to the discovery of novel biomarkers 6,7, disease subtypes, and treatment targets. Meanwhile, AIM-HI UC is the only AI-powered Geboes scoring tool that provides automated subgrade-level scores to accurately and reproducibly measure histological stage and improvement for ulcerative colitis research and clinical trials. “We are thrilled to collaborate with the Crohn’s & Colitis Foundation, the leading nonprofit organization in the IBD space, as a preferred partner to meaningfully advance our understanding of IBD through this unique combination of datasets,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “By partnering with PathAI, we aim to uncover valuable insights from well-characterized pathology images, enhancing our understanding of IBD at the microscopic level and paving the way for novel biomarkers, refined disease subtypes, and potential therapeutic targets,” said Angela Dobes, SVP IBD Plexus, Crohn’s & Colitis Foundation. By combining IBD Plexus’ deeply curated multimodal data, including its large-scale digitized pathology archive, with advanced AI analysis by PathAI, this collaboration aims to enhance researchers’ understanding of the histological factors of IBD to drive novel discoveries that improve quality of life for the millions of Americans living with these diseases. For more information on licensing a joint dataset from PathAI and the Crohn’s and Colitis Foundation, please reach out to bd@pathai.com. Register for a free demo of PathAI’s algorithm products here. Footnotes IBD Explore and AIM-HI UC are For Research Use Only. Not for use in diagnostic procedures. Danese S. et al. Unmet medical needs in ulcerative colitis: an expert group consensus. Dig. Dis. 2019;37(4):266–283. doi: 10.1159/000496739. https://www.ncbi.nlm.nih.gov/pubmed/30726845 Colombel J.F. et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut. 2017;66(12):2063–2068. doi: 10.1136/gutjnl-2016-312307. https://www.ncbi.nlm.nih.gov/pubmed/27590995 Colombel J.F. et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779–2789. doi: 10.1016/S0140-6736(17)32641-7. Alsoud D. et al. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021;6(7):589–595. doi: 10.1016/S2468-1253(21)00065-0. Shamshoian et al. 2024. United European Gastroenterology Week. ePoster PP0375. Griffin et al. 2024. European Crohn’s and Colitis Organisation. P008. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples, with the potential to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com. About the Crohn’s & Colitis Foundation The Crohn’s & Colitis Foundation is the leading nonprofit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohn’s disease and ulcerative colitis and improving the quality of life for the millions of people living with IBD. The Foundation’s work is dramatically accelerating the research process, while also providing extensive educational and support resources for patients and their families, medical professionals, and the public. To learn more about the IBD Plexus program, visit www.crohnscolitisfoundation.org/research/plexus. Contact Details SVM Public Relations and Marketing Communications +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

October 03, 2024 10:00 AM Eastern Daylight Time